[ad_1]
MediConnect will solve the key problems for the NHS and throughout the pharmaceutical industry. This includes monitoring of reputable manufacturers' medicines, wholesalers, prescribers and pharmacies. Preventing patients from accessing drugs from multiple pharmacies at the same time; the removal of counterfeited drugs from distribution and the simplified recall of drugs prescribed at any time through the pharmaceutical industry.
Excessive use of prescription drugs only happens because a healthcare professional does not know or does not have an up-to-date history of a patient's prescription history. There is no single point of information that maintains a record of recently prescribed drugs across the industry as a whole.
This is verified by the CQC report, stating that 43% of online prescribers were dangerous. A further investigation conducted by Pulse revealed that at least 11 of the 35 online prescription pharmacies inspected by the CQC were criticized for not informing treating physicians when they treated their patients.
The figures are amazing! The cost for the NHS has increased astronomically, with opioids alone costing the taxpayer 263 million pounds in 2017, it is estimated that 2,000,000 Britons are considered chronic users of painkillers. Furthermore, admissions to the private detox center have increased by 30% in the last two years.
Dexter Blackstock, director of MediConnect said:
"I joined the pharmaceutical industry and became a business partner with Joe Soiza, founder of UK Meds. Initially, we were shocked to learn that there was no centralized solution that allowed pharmacies and general practitioners to determine what it was prescribed to a patient and, more importantly, when.This is exactly why MediConnect was formed, to save lives and improve the system to provide a level of transparency for pharmacies and general practitioners who prescribe drugs to their patients ".
It is also worth noting that patients are already aware of potential threats to the supply chain. During the 2007 Casodex, Plavix and Zyprexa scandal, the Regulatory Agency for Medicines and Health Products (MHRA) seized 40,000 packages of fake drugs before being distributed to pharmacies, but 25,000 parcels have reached pharmacies across the United Kingdom and have been dispensed to patients. After a recall, another 7000 packages were recovered.
The MediConnect blockchain solution aims to address these issues and the technology that allows them to do so is now available. In addition, to solve these problems, MediConnect provides its blockchain solution as an opportunity to introduce a token, the MediConnect (MEDI), as a unit of value.
The MediConnect solution will be composed of two blockchains: first, a private blockchain authorized to store confidential data of the client's prescriptions and the data of the origin of the drugs. This type of blockchain is often referred to as Distributed Ledger Technology (DLT). Secondly, a public blockchain that will manage the MEDI transactions related to the purchase of drugs, loyalty programs and will finance the Smart Contracts integrated into the MEDI platform. Both blockchains will be implemented using the Stratis Technology Stack.
To learn more about MediConnect and how they are aiming to revolutionize the pharmaceutical industry to save lives, visit their website below.
Company website: mediconnect.io.
[ad_2]Source link
